北京时间2024年11月11日,生物技术公司阿卡迪亚制药(ACAD.US)股价出现罕见大涨,截至收盘时报18.56美元,涨幅高达5.63%。
分析人士认为,市场对阿卡迪亚公司未来发展前景仍持乐观态度。该公司主攻治疗中枢神经系统疾病的创新药物研发,旗下在研管线包括帕金森症、阿尔茨海默症和精神分裂症等重大疾病的潜在新药。虽然近期未有重大利好消息,但投资者对公司长期增长潜力仍有信心。
此外,阿卡迪亚最新财报数据也令投资者增强信心。数据显示,公司营收、净利润和毛利均保持稳健增长,每股收益达0.20美元。机构投资者对该股的评级也较为乐观,有65%机构给予"买入"评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.